32 results
8-K
EX-99.1
GLTO
Galecto Inc
27 Jan 22
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
8:31am
, inflammation-associated micro- thrombosis and those of short or long-term fibrosis. Patients treated with GB0139 had a significantly greater rate of decline … patients; that GB0139 has the potential to counter the cytokine storm, inflammation-associated thrombosis, short and long-term fibrosis and multi-organ
8-K
EX-10.1
GLTO
Galecto Inc
9 Feb 22
Departure of Directors or Certain Officers
4:30pm
. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long- term basis, high-caliber
S-1/A
EX-10.6
GLTO
Galecto Inc
22 Oct 20
IPO registration (amended)
6:13am
. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber
8-K
GLTO
Galecto Inc
15 Aug 23
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
8:00am
, Galecto’s next step in the development of GB1211 is to initiate a long-term, randomized, placebo-controlled, Phase 2a trial in patients with decompensated
8-K
EX-10.1
GLTO
Galecto Inc
23 Nov 20
Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors
4:15pm
. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long- term basis, high-caliber
8-K
EX-99.1
3v3 y7t0x
15 Aug 23
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
8:00am
8-K
EX-99.1
au5urob
5 Jan 22
Regulation FD Disclosure
4:02pm
8-K
EX-99.1
s5igvvw59n
5 Jan 21
Results of Operations and Financial Condition
4:31pm
10-Q
bzl 4cadoz
11 Dec 20
Quarterly report
7:30am
PRE 14A
s7ulz 2zfzgdtuisu
16 Apr 24
Preliminary proxy
4:00pm